Last reviewed · How we verify
NCT06342765: FixedD3
Safety and Performance of the SpineVision Posterior Fixation Systems in Thoracolumbar Spinal Treatment
trial testing Pedicle fixation surgery in Intervertebral Disc Degeneration in 330 participants. Currently enrolling.
30 May 2028
Quick facts
| Lead sponsor | SPINEVISION SAS |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 330 |
| Start date | 22 September 2022 |
| Primary completion | 30 May 2028 |
| Estimated completion | 30 May 2028 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Pedicle fixation surgery
Conditions studied
- Intervertebral Disc Degeneration — all drugs for Intervertebral Disc Degeneration →
Sponsor
SPINEVISION SAS — full company profile →
Who can join
18 and older, any sex, with Intervertebral Disc Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to confirm the safety and performance of the three (3) Spinevision posterior fixations systems Lumis®, Plus® and Ulis® , in the treatment of patient suffering from thoracolumbar spinal degenerative pathologies, or degenerative disc disease (disease that occurs when the spinal disk break down) associated pathologies. Part of their standard of care, participants will be questioned on their back and leg pains, their disability and if they have encountered any adverse effects since the Spinevision posterior fixation system implant surgery. Those data will be collected up to twenty four (24) months after the Spinevision posterior fixation system implant surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06342765
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intervertebral Disc Degeneration
Currently open trials in the same condition.
- NCT07168603 — EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease · Phase 1, PHASE2 · recruiting
- NCT05299762 — A Post Market Surveillance on INFUSE Bone Graft · recruiting
- NCT05648474 — Intraoperative Monitoring for the Lateral Lumbar Interbody Fusion Procedure · recruiting
- NCT05997121 — Safety and Performance of the Hexanium TLIF System in the Treatment of Degenerative Disc Disease · recruiting
- NCT06155409 — Safety and Performance of the SPINEVISION Hexanium ACIF in the Treatment of Cervical Spine Degenerative Disc Disease · active not recruiting
Other SPINEVISION SAS trials
Trials by the same sponsor.
- NCT05997121 — Safety and Performance of the Hexanium TLIF System in the Treatment of Degenerative Disc Disease · recruiting
- NCT06155409 — Safety and Performance of the SPINEVISION Hexanium ACIF in the Treatment of Cervical Spine Degenerative Disc Disease · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06342765 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SPINEVISION SAS
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06342765.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing